Subchronic Effects of Olanzapine on Sleep EEG in Schizophrenic Patients with Predominantly Negative Symptoms

6533b82ffe1ef96bd1295d2e

RESEARCH PRODUCT

Subchronic Effects of Olanzapine on Sleep EEG in Schizophrenic Patients with Predominantly Negative Symptoms

Klaus Mann Matthias J. Müller Joachim Röschke Otto Benkert Florian Müller-siecheneder Hermann Wetzel M Blümler W. Rossbach Ralf W. Dittmann H. Russ

subject

Adult Male Olanzapine Adolescent Polysomnography medicine.medical_treatment Polysomnography Severity of Illness Index Drug Administration Schedule Benzodiazepines Surveys and Questionnaires medicine Humans Pharmacology (medical)Antipsychotic Sleep disorder Sleep Stages medicine.diagnostic_test Electroencephalography General Medicine Middle Aged medicine.disease Sleep in non-human animals Diagnostic and Statistical Manual of Mental Disorders Psychiatry and Mental health Delta Rhythm Olanzapine Schizophrenia Anesthesia Delta Rhythm Schizophrenia Schizophrenic Psychology Sleep Stages Psychology Antipsychotic Agents medicine.drug

description

Background It is well known that sleep disturbance is an integral symptom of schizophrenia. In recent studies, a deficit of delta sleep has been observed in schizophrenic patients. Antipsychotic drugs with serotonin (5-HT2) receptor-antagonistic properties are considered to have delta sleep promoting effects. We have investigated the effects of subchronic olanzapine treatment on sleep EEG in schizophrenic patients. Methods The effects of administration of olanzapine (15 to 20 mg) on sleep were studied for four weeks in 10 male, drug-free patients suffering from schizophrenia with predominantly negative symptoms. Conventional sleep EEG parameters were investigated at baseline and after treatment with olanzapine for four weeks. Additionally, spectral power analysis of the EEG signal in distinct frequency bands was computed for different sleep stages. Psychopathology (PANSS, HAMD-17, HAMA) and side effects were assessed weekly. Results All patients improved, as measured by PANSS global scores. Compared to baseline, there was a significant improvement of parameters of sleep efficiency and an increase of delta sleep as well as REM sleep. Regarding spectral power values, no significant differences between baseline and treatment conditions were found. Conclusions Sleep improvement was due to parameters of sleep efficiency and delta sleep, which may be related to serotonin antagonistic properties of olanzapine.

year	journal	country	edition	language
2004-10-07	Pharmacopsychiatry

https://doi.org/10.1055/s-2004-827170